Arcus Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on the discovery and development of cancer immunotherapy. Its pipeline includes AB928, AB680, AB122, and AB154. AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.It is in the Phase-I clinical trial. AB680 is a potent and selective inhibitor of CD73 and is in the pre-clinical stage of development. AB122 is an anti-PD-1 antibody and is in the Phase-I dose-escalation trial. AB154 is a humanized anti-TIGIT antibody.